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Abstract 
We have previously demonstrated a crucial role of NUPR1 in tumor development and progression. In this 
work we report the functional characterization of a novel Nupr1-like isoform (NUPR1L) and its functional 
interaction with the protumoral factor NUPR1. Through the use of primary sequence analysis, threading, and 
homology-based molecular modeling as well as expression and immunolocalization, studies reveal that 
NUPR1L displays properties which are similar to member of the HMG-like family of chromatin regulators 
including its ability to translocate to the cell nucleus and bind to DNA. Analysis of the NUPR1L promoter 
showed the presence of two p53-response elements at positions -37 and -7 respectively. Experiments using 
reporter assays combined with site-directed mutagenesis and using cells with controllable p53 expression 
demonstrate that both of these sequences are responsible for the regulation of NUPR1L expression by p53. 
Congruently, NUPR1L gene expression is activated in response to DNA damage induced by Oxaliplatin 
treatment or cell cycle arrest induced by serum starvation, two well-validated methods to achieve p53 
activation. Interestingly, expression of NUPR1L down-regulates the expression of NUPR1, its closely related 
protumoral isoform, by a mechanism that involves the inhibition of its promoter activity. At the cellular level, 
overexpression of NUPR1L induces G1 cell cycle arrest and a decrease in their cell viability, an effect that is 
mediated, at least in part, by down-regulating NUPR1 expression. Combined these experiments constitute the 
first functional characterization of NUPR1L as a new p53-induced gene which negatively regulates the 
protumoral factor NUPR1. This article is protected by copyright. All rights reserved 
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Introduction 
The Nuclear Protein 1 (NUPR1), also known as p8 and Com1, is a stress-induced gene that was first 
identified in pancreas because its activation during the acute phase of pancreatitis (Mallo et al., 1997). This 
gene encodes an 82 amino acid polypeptide with a theoretical molecular mass of 8872.7 Da and a pI of 9.98. 
NUPR1 is an evolutionary conserved gene present in Drosophila, Xenopus and mammals but not in yeast. 
Despite NUPR1 being structurally related to the HMG (high-mobility group) transcriptional regulators 
(Encinar et al., 2001), it currently does not share significant homology with any other protein. NUPR1 is a 
basic helix-loop-helix molecule that contains a canonical bipartite nuclear localization signal (NLS) (Vasseur 
et al., 1999) and an N-terminal PEST (Pro/Glu/Ser/Thr-rich) region indicating a possible regulation by the 
ubiquitin/proteasome system (Goruppi and Kyriakis, 2004) and suggesting a role in transcriptional regulation 
(Goruppi and Iovanna, 2010; Urrutia et al., 2014). Nupr1is considered as a stress protein because it is induced 
in response to several injurious stimuli, such as hypoxia, apoptosis inducers, glucose starvation and several 
anticancer agents. Likewise, NUPR1 is overexpressed in several types of human cancers, including pancreatic 
ductal adenocarcinoma (PDAC) (Su et al., 2001) and its metastasis (Ree et al., 2000), suggesting a crucial role 
in cancer biology (Cano et al., 2014; Vasseur et al., 2002). Therefore, during the last decade we have focused 
our studies on the role of NUPR1 on cancer, especially on PDAC which remain one the most lethal tumor 
diseases. In this regard, we have demonstrated in our recent studies the crucial function of NUPR1 as a 
cooperator factor with the oncogenic form of Kras
G12D
 to promote Pancreas Intraepithelial Neoplasias (PanIN) 
in vivo and in vitro (Cano et al., 2014; Grasso et al., 2014; Hamidi et al., 2012a; Vasseur et al., 2002).  
The recent detailed analysis of databases reveals the presence of a NUPR1-related sequence in human genome 
and consequently denominated NUPR1-Like (NUPR1L). NUPR1 and NUPR1L have been recently proposed 
as members of a new family of small chromatin regulators based on theoretical dynamic analysis of their 
spatial structure (Urrutia et al., 2014). Due to the critical role of NUPR1 in cancer development and 
progression, our aim was to study the function of NUPR1L, as well as the possible interaction with its 
homologous, NUPR1, in order to shed additional light to the NUPR1-associated cancer processes which 
remains poorly understood at the mechanistic level. To this end, we have cloned both the cDNA and the 
promoter region of human NUPR1L into vectors that have allowed us to analyze the function and regulation 
of this protein. In this paper, we demonstrated that NUPR1L is a new direct p53 target gene which down-
regulates the tumorigenic gene NUPR1 at the transcriptional level by repressing the activity of its promoter. In 
addition, the NUPR1L-induced decrease in pancreatic cancer cells viability is rescued by the forced 
expression of NUPR1 showing a functional interaction between them. Thus, because of the key role of 
NUPR1 in cancer, the new information emerging from this study has biomedical relevance that aid to a better 
understanding on the pathobiology of cancer. 
 
Material and Methods 
Primary structure analysis and bioinformatics tools. 
NUPR1L sequence was obtained using the NCBI database (Reference Sequence: NP_001139184.1). NLS 
motif was determined by ELM (Eukaryotic Linear Motifs) server (http://elm.eu.org/)(Dinkel et al., 2012). 
Putative p53-sites binding of NUPR1L promoter were evaluated using web-based tools to identify conserved 
patterns in sequences (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) (Farre 
et al., 2003). NUPR1 and NUPR1L sequences were compared by pairwise alignment 
(www.ebi.ac.uk/Tools/msa/clustalw2/). 
Cell culture. The immortalized Mouse Embryonic Fibroblasts (MEFs), 3T3, 10.1 and (10.1)Val5, were a 
kind gift from Levine AJ (Harvey and Levine, 1991; Wu and Levine, 1994). MEFs, HEK-293T (human 
embryonic kidney cells), MCF-7 (breast cancer cells), Hela (cervical cancer cells) and pancreatic cancer-
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derived cell lines, Capan-2, Panc-1 and MiaPaca-2, parental and transduced, were maintained in DMEM 
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS at 37°C with 5% CO2 in a humidified 
atmosphere and manipulated following ATCC’s recommendations. To induce DNA damage, MCF-7, Capan-
2 and Hela cells were treated with increasing concentrations of Oxaliplatin (10, 20 and 40 µM) for 18 and 24 
h. For FBS starvation, cells were maintained in serum-free DMEM for 12, 24 and 60 h. Glucose starvation 
was obtained by cultivating cells with DMEM (no glucose) (Invitrogen, Ref# 11966) supplemented with 10% 
FBS for 24 h.  
DNA constructs. According to the predicted cDNA sequence of human (Accession No. ENSG00000185290) 
deposited in GenBank, two gene-specific primers were designed to amplify 5’-cDNA and 3’-cDNA ends of 
Nupr1L mRNA from human embryonic kidney 293T cells using Trizol reagent (Invitrogen) and ImProm-II 
Reverse Transcription System (Promega). Nupr1L mRNA was obtained from HEK-293T cells because are 
normal human cells. PCR was performed under the following conditions: 5 min at 95°C for denaturation, 
followed by 25 cycles (10 sec at 98°C, 1 min at 65°C and 1 min at 72°C) of reactions, ending with a 5-min 
extension at 72°C (GoTaq® DNA Polymerase, Promega). The primers used are listed in Table S2. The full-
length cDNA for human NUPR1L was subcloned into pCCL-WPS-PGK vector modified to express 6-
histidines and a Flag at N-terminus of the expressed protein (6His-Flag-Nupr1L), using BamHI and XhoI 
restriction sites. Genomic DNA fragment (-159/+179) corresponding to the NUPR1L promoter was cloned 
into luciferase pGL3-basic (Promega) reported plasmid using MluI and BglII restriccion sites (pGL3-Nupr1L-
luciferase). Human genomic DNA from mononuclear cells was used as a PCR template. PCR conditions are 
reported above. The potential p53-binding sequences of NUPR1L were mutated using the QuikChange®II-E 
Site-Directed Mutagenesis Kit (Agilent Technologies). The primers used are listed in Table S2. Plasmids 
were verified by DNA sequencing. The Nupr1 promoter (-2111/+229) which is cloned into the luciferase 
pGL3-basic reported plasmid (pGL3-Nupr1L-luciferase) was a kind gift from Bartholin L. (INSERM U1052, 
France) (Pommier et al., 2012). 
Transductions. Lentiviral particles were generated by transfecting HEK-293T cells as reported previously 
(Bonacci et al., 2014). Briefly, HEK-293T cells were transfected with a mix of pCCL construct (Nupr1L, 
Nupr1 or GFP), Helper (carries sequence necessary for viral assembly of lentivirus) and pVsVg (expresses the 
vesicular stomatitis virus envelop glycoprotein G pseudotype), using Lipofectamine reagent (Invitrogen) and 
following manufacturer’s recommendations. Viruses containing medium was collected and filtered through a 
0.2 μm filter. MiaPaCa-2 and Hela cells were grown at 50%-60% confluence and infected with the 
supernatant containing viruses. Cells were used for experiments 72-96 hours after transduction. Expression of 
GFP was verified by fluorescence microscopy and NUPR1L expression controlled by western blot.  
siRNA transfection. Cells were plated at 70% confluence. Nupr1 and Nupr1L were knockeddown using 140 
ng of specific siRNA. INTERFERin reagent (Polyplus-transfection, New York, NY, USA) was used to 
perform siRNA transfections according to the manufacturer’s protocol. Scrambled siRNA targeting no known 
gene sequence was used as negative control. The sequences of the siRNA used are shown in Table S2. 
Immunofluorescence. Transduced cells with the lentiviral vector 6His-Flag-Nupr1L, as previously 
described, were cultured on glass coverslips, fixed, permeabilized, and incubated with mouse monoclonal 
anti-Flag (M2, Sigma) followed by Alexa Fluor antimouse IgG 488 (Invitrogen) secondary antibody. Samples 
were mounted in ProLongAntifade Reagent with DAPI (Invitrogen) and examined in an Eclipse 90i Nikon 
microscope (Nikon Instruments Europe B.V., Champigny-sur-Marne, France). 
Reporter gene assay. The reporter assays were performed with Luciferase Assay System (Promega) 
according to the manufacturer’s instructions. Cells were plated in 24-well plates and the following day co-
transfected with 200 ng of pGL3-Nupr1L-luciferase, pGL3-Nupr1-luciferase or 6His-Flag-Nupr1L, and 20 ng 
of pRL-SV40 plasmids. The concentrations of pcDNA3-p53 were 200, 400 and 800 ng, under the needs of 
each experiment. Transient transfections were performed using Lipofectamine 2000 reagent (Invitrogen), 
according to the manufacturer’s protocol. The luciferase reporter activity of each sample was normalized 
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against the internal control activity of Renilla luciferase developed with coelenterazine (Sigma-Aldrich). Each 
sample was determined in triplicate. The results represent means ± S.D. from three experiment runs. 
RT-qPCR. RNA from cells was prepared using Trizol reagent (Invitrogen). cDNA was obtained using the 
ImProm-II Reverse Transcription System (Promega). Real-time quantitative PCR was performed in a 
Stratagene Cycler (La Jolla, CA, USA) using GoTaq® qPCR Master Mix and ROX reference dye (Promega). 
Sequences of the primers used to amplify human genes are indicated in Supplementary Table 2. 
Immunobloting. Protein extraction was performed on ice using total protein extraction buffer: 50 mM 
HEPES (pH 7.5), 150 mM NaCl, 20% SDS, 1mM EDTA,1 mM EGTA, 10% glycerol, 1% Triton, 25 mM 
NaF, 10 mM ZnCl2 and 50 mM DTT. Before lysis, protease inhibitor cocktail at 1:200 (Roche Applied 
Science, Meylan, France), 500 mM PMSF, 1 mM sodium orthovanadate and 1 mM β-glycerophosphate were 
added. Protein concentration was measured using a BCA Protein Assay Kit (Pierce Biotechnology). Protein 
samples (95 µg) were denatured at 95°C and subsequently separated by SDS-PAGE gel electrophoresis. After 
being transferred to PVDF, the membrane was blocked with 1% BSA, and then the samples were probed with 
primary antibody, followed by a horseradish peroxidase-coupled secondary antibody. Primary antibodies used 
were mouse monoclonal anti-Flag (M2) and anti-β-tubulin polyclonal from Sigma-Aldrich. Image acquisition 
was made in Fusion FX image acquisition system (Vilber Lourmat, VWR, Fontenay-sous-Bois, France). 
Flow cytometry. Cell cycle analysis was performed by standard propidium iodide (PI) staining protocol 
(Grasso et al., 2014) MiaPaCa-2 cells were seeded at a density of 500,000 cells per well in a 6-well tissue 
culture plate. Then, cells were trypsinized, fixed in 70% ethanol, and stained with PI. Acquisition of 50,000 
events per sample was made in a MACSQuant-VYB flow cytometer (Miltenyi Biotec, Surrey, UK). Data 
analysis was performed using the FlowJo (Treestar, Ashland, OR, USA) software.  
Cell viability. Transduced cells were seeded at a density of 5,000 cells per well in a 96-well opaque-walled 
tissue culture plates compatible with fluorometer. Cell were allow to attach overnight and the following day 
plate was removed from the 37°C incubator, and 20 μL/well CellTiter-Blue™ (Promega, USA) were added. 
Cells were incubated with the reactive using standard cell-culture conditions for 24 h. Then, the plate was 
shaken for 10 seconds, and fluorescence was recorded at 560/590 nm (TriStar LB 941 Multimode Microplate 
Reader, Berthold Technologies). Cell viability in GFP infected cells was normalized to 100%.  
Proliferation assay using iCELLigence System. A real-time cell proliferation assay was conducted using 
the iCELLigence System, (ACEA Biosciences, San Diego, CA). This system uses measurement of electrical 
impedance, created by cells attached to the microelectrode-integrated cell culture plated to measure cell 
proliferation in real time. A dimensionless parameter termed cell index (CI) was derived to represent cell 
status based on the measured relative change in electrical impedance that occurs in the presence and absence 
of cells in the wells (Irelan et al., 2011; Urcan et al., 2010). Prior to experiment, transduced cells were 
trypsinized and counted with Luna Counter Cells (Logos Biosystems) for getting exactly 40,000 cells in each 
well with 300 µl of DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS. Then, 
proliferation was followed using iPad and the specific application which was able to synchronize with the 
device and measure the impedance minutes after minutes for a total of 72 h. 
Statistical analysis. Results presented in the text, tables and figures are means and standard deviation (S.D.). 
Before mean comparison, normality of data was checked by using the Kolmogorov-Smirnov test. For 
variables with a normal distribution, Student-T Test and one-way ANOVA with post hoc LSD test were used 
to compare the significance of differences between experimental groups. For variables lacking a normal 
distribution, either Mann-Whitney U test or Kruskal-Wallis one-way analysis of variance were applied. SPSS 
20.0 software was used (SPSS Inc., Chicago, IL, USA). Only values of P < 0.05 were considered significant. 
RT-qPCR data are representative of at least three independent experiments with technical duplicated 
completed.  
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Results 
NUPR1L is a protein with nuclear localization that displays homology with NUPR1 
Our laboratory has extensively characterized the structure and function of NUPR1, a chromatin factor with 
similar biochemical properties to HMG proteins (Encinar JA, 2001). Interestingly, analyses of RNA-Seq data 
derived from pancreatic cancer cells as well as the EST database (NCBI) revealed the existence of a NUPR1-
like protein (NUPR1L), which shares sequence homology, predicted molecular, mass, and isoelectric point 
with NUPR1. NUPR1L is found located on chromosome 7 (7p11.2) and contains 2 coding exons that encode 
a 97 amino acids polypeptide (NM_001145712). The Nupr1 gene is positioned on chromosome 16 (Vasseur 
et al., 1999). Similar to NUPR1, this previously uncharacterized protein also shares many properties with 
members of the HMG family of transcriptional regulators which are composed by intrinsically-disordered 
non-histone chromosomal proteins containing DNA-binding domains, called AT-hooks (DBD), which bind to 
the minor groove of short stretches of AT-rich DNA (Fonfría-Subirós E, 2012). These AT hooks (DBDs) are 
formed by a conserved sequence, which is rich in Glycine, Arginine, and Lysine (Fonfría-Subirós E, 2012). 
The first HMG AT-hook, DBD1, differs from DBD2 and DBD3 by the absence of single Proline residues that 
flank the G/R/K-rich core of this domain. Interestingly, we found that, similar to NUPR1, NUPR1L contains a 
single AT-hook domain, which is similar to the HMGA1 DBD1 but lacks significant homology to this protein 
outside of this region (Figure 1a). Based upon the high homology of NUPR1 and NUPR1L (Figure 2a), we 
built a model of NUPR1L using threading algorithms, a method that has been ranked by the structural biology 
community as one of the top systems for protein structure prediction in the CASP7 (Zhou et al., 2007), 
CASP8 (Zhang, 2009), CASP9 (Xu et al., 2011), and CASP10 (Zhang, 2012) experiments. The NUPR1L 
model was generated using as input the FASTA file corresponding to the NCBI-deposited primary structure 
and the I-TASSER software. According to this model, NUPR1L has the propensity to adopt a helix-loop-helix 
fold, a domain evolutionarily associated with DNA-binding proteins (Figure 1b). To estimate this model 
quality, we subsequently generated Ramachandran plots (Psi vs. Phi angles plot) using PROCHECK 
(Laskowski R A, 1993). The NUPR1L model had the best overall geometry with 97% of residues in favored 
and allowed regions (Supplementary Figure 1a). The properties of this energy minimized model, display 
several regions within NUPR1L which the propensity to form three α helices. Helix 1 contains 15 residues 
and spans from 19 to 34. Helix 2 contains 9 residues and spans from 52 to 61 while Helix 3 contains 20 
residues and spans from 67 to 87 (Supplementary Figure 1b and c). Comparisons with experimentally solved 
structures deposited in the PDB bank indicated that NUPR1L not only shares structural properties with the 
previously identified most related protein NUPR1 but also with HMGA1 (PDB 2E6O). Thus, the two proteins 
share the propensity to form H-L-H motifs and share AT-hook-like DNA binding motif. Next, we utilized the 
previously reported structural features of both NUPR1 and HMGA1 to infer insights into the biochemical 
properties of NUPR1L by performing comparative linear motif analyses. Linear motif analyses by Psort II 
predicts typical NLS signal with a pattern of K (K/R) X (K/R) between residues 70 to 86 (Figure 2b) (Nakai 
K, 1999). In fact, the spacing of these sequences in 3D, as shown in Figure 1c, has ligand properties expected 
of a bipartite receptor for α-importins, which transports proteins to the nucleus. These results are congruent 
with the nuclear localization of Nurp1L determined experimentally by immunofluorescence (Figure2b). For 
the identification of residues involved in DNA binding by NUPR1, we used DP-Bind (Hwang S, 2007). This 
software implements three machine learning methods, namely support vector machine (SVM), kernel logistic 
regression (KLR), and penalized logistic regression (PLR) to predict DNA and RNA-binding residues from 
primary structure features, including the side-chain pKa value, hydrophobicity index and molecular mass of an 
amino acid (Hwang S, 2007). Figures 1d and 1e provides a graphic representation of the results obtained with 
this approach, which predicted that the sequences GRSKGRTRR have the potential to bind to DNA. 
Interestingly, this sequence is similar to the DNA binding residues found in the AT-hook-like motifs of both 
NUPR1 (GRKGRTKR) and HGMA1 (GRPKGSKNK). Our prediction of a DNA-binding domain within the 
sequence of NUPR1L prompted us to generate a model of this protein bound to DNA. For this, we applied 
two well-validated methods. We developed a homology-based model, which relies upon the previously solved 
NMR structure of the first hook of the HMGA1 bound to DNA (PDB: 3UXW), as the first 3D approach to 
characterize the NUPR1L DNA binding domain. Because of its simplicity, this model lent itself to the 
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simplicity of using manual docking to superimpose the corresponding region of NUPR1L to the highly 
homologous HMGA1 AT-hook (Figure 1d and 1e). The NUPR1-DNA complex obtained through this 
homology-based approach is shown in Figure 1d and 1e. This complex was maintained through the bonding 
interactions, listed in Supplementary Table 1a. The second method, DP-Dock uses a nonspecific B-DNA to 
probe the binding site on a 3D model of a protein, which is known to bind DNA, but for which the specific 
amino-acid-to-nucleic-acid-base-contacts are unknown. Given the structure of a DNA-binding protein, the 
method first generates, automatically, an ensemble of protein-DNA complexes obtained by rigid-body 
docking with a nonspecific canonical B-DNA molecules with the sequence A10-T10 (Gao M, 2009). Models 
are subsequently selected through clustering and ranking by their DNA-protein interfacial energy (Gao M, 
2009). Figure 1d and 1e shows that this method was successful in generating a NUPR1L-DNA complex 
where the amino acid-to-base contacts were primarily given by the same GRSKGRTRR sequence identified 
through DP-bind, as shown in Figure 1d and 1e. The ionic and hydrogen-bonding interactions that define the 
protein-DNA binding interphase are listed in Supplementary Table 1a. In addition, analyses of the DNA 
bound NUPR1L complex confirmed that this protein prefers to recognize the minor groove of DNA. 
Together, the results of these analyses support the existence of a high level of similarity between Nurp1 and 
Nurp1L and HMGA1. In addition, the models generated through these comparative modeling approaches 
constitute a step forward toward the understanding how Nurp1L binds to -importin for localizing to the 
nucleus where it can use its distinct AT-hook to bind to the minor groove of DNA (Supplementary Table 1b), 
a characteristic previously reported for the structurally related HMGA protein to facilitate transcription 
initiation by several regulators of gene expression. 
NUPR1L is a new p53 target gene that is regulated by two functional binding sites in its promoter 
region 
We have previously shown that NURP1 mediates pancreatic cancer initiation and promotion by mediating 
downstream signal from mutated tumor suppressor such as p53. This knowledge led us to begin studies on the 
regulation of NUPR1L gene expression by first analyzing its promoter region using bioinformatics-based 
transcription factor binding site analyses (Farre et al., 2003). Analysis of the 643 bp core promoter region for 
the NUPR1L gene identified consensus cis-regulatory sites for E2F-1, C/EBP, C/EBP, AP-1, GATA-1, 
NFB, ATF-1 as well as two p53-binding sites (see Figure 3a). These sites, which conform to the typical p53 
binding sequence (GGGCAGG) are located at positions -37 and -7 of the promoter, respectively (Figure3a). 
Thus, we generated the pGL3-Nupr1L-Luc constructs, containing these p53-binding sites to be used in 
reporter transcriptional studies which we performed in three different cancer cell lines by co-transfection with 
a wild-type p53 expression vector. Notably, these experiments demonstrate that the Nupr1L promoter is 
activated by p53 in a dose-dependent manner reaching a maximal upregulation of 4.78 (± 0.37) fold using 800 
ng of the p53 encoding plasmid (Figure3b). A similar response was observed in Hela cells (Figure3d). In 
breast cancer cells, the Nupr1L promoter activity was increased by 5.87 (± 0.65) fold in response to only 200 
ng of the p53 construct (Figure3c). Subsequently, we use site directed mutagenesis to inactivate the p53 
binding site at both the position -37 (ΔS1 mutation) and -7 (ΔS2 mutation) (Figure4a) and repeated the 
reporter assays under the same conditions described above (Figure4b-d). Interestingly, mutation of one of 
these p53-binding sites independently did not eliminate the induction effect of the p53 expression suggesting 
that both sites are necessary for achieving the upregulation of Nupr1L promoter activity by p53. 
Consequently, inactivation of both p53-binding sites (ΔS1+ΔS2 mutation) (Figure 4a) completely abolished 
the activating effect of p53 in the three different cell lines studied. These results demonstrate that Nupr1L is 
regulated by p53 at the promoter level and defines the key cis-regulatory sequences responsible for this effect. 
NUPR1L expression is highly dependent of p53 
Through promoter studies described above, we demonstrated that NUPR1L is regulated by p53. However, we 
needed to know and to quantify in a more elegant manner the p53 dependence in the expression of NUPR1L. 
For this, three cell lines characterized by a different p53 status were transfected with the pGL3-Nupr1L-Luc 
construct and the promoter activity was evaluated by luciferase assay. We used immortalized fibroblasts 





 (10.1 cell line) and a termosensible (ts) mutant, p53
-/ts
 named (10.1)Val5 cell line. In fact, 10.1 
cell line is an established Balb/c 3T3 line that has lost both p53 alleles during immortalization (Harvey and 
Levine, 1991). (10.1)Val5 is a clonal cell line derived from the 10.1 cells by stable transfection of the 
temperature-sensitive p53 mutant (val135) driven by the Harvey sarcoma virus long terminal repeat 
(Michalovitz et al., 1990). p53 exists in a mutant (inactive) conformation in this cell line at 39°C; temperature 
shift to 32°C results in wild-type p53 conformation and activity. At 37°C, both mutant and wild-type p53 
conformational forms co-exist in the cells as previously demonstrated (Martinez et al., 1991; Wu et al., 1993). 






 cells where both wild-
type p53 and inactive conformational forms were present (Figure 5). p53
+/+
 cells showed a significant increase 
in the promoter activity compared with the control vector (6.8 ± 1.1 folds). In the same way, luciferase assay 
displayed a 9.2-fold (± 0.9) increase in termosensible p53 cells, and only 2.3-fold (± 0.4) when growth at 




 cell line (p = 
0.05). Altogether these results demonstrate a high and significant dependence of p53 activation in the 
NUPR1L regulation. 
p53-inducing classical stimuli increase NUPR1L expression in cancer cells 
The p53 tumor suppressor protein is a key regulator of cell-cycle arrest, survival, DNA repair, programmed 
cell death, and genetic stability. The expression and function of p53 is activated in response to several cellular 
stresses including serum starvation, DNA damage, and a wide range of chemotherapeutic drugs (Levine et al., 
2006; Vazquez et al., 2008). Thus, having demonstrated that the Nupr1L promoter is responsive to p53, we 
next aim at studying whether or not classic treatments that trigger p53 activation, such as DNA damage by 
Oxaliplatin or cell cycle arrest induced by serum starvation, ultimately impact on the expression of the 
NUPR1L gene. For this purpose, we treated three cancer cell lines, which have preserved p53 wild-type, with 
increasing concentrations of Oxaliplatin for 18 or 24 h and measured NUPR1L mRNA expression by RT-
qPCR. The results of these experiments depicted in Figure 6 demonstrate that Nupr1L mRNA is induced in a 
dose-dependent manner. The levels of NUPR1L mRNA were increased by almost 12 fold in MCF-7 cells 
upon the treatment with Oxaliplatin at 40 µM for 24 h (11.7 ± 2.9 folds) (Figure6a). A significant, although 
less robust increase in Nupr1L mRNA was also obtained in Capan-2 and Hela cells after of 18 h of treatment 
with 20 µM of Oxaliplatin (Figure6b and6c). Changes in Nupr1L mRNA levels were also evaluated following 
serum starvation after of 12, 24 and 60 h, a treatment that induces cell cycle arrest and p53 activation (Del Sal 
et al., 1995; Schneider et al., 1988). Congruently, as shown in Figure 6 Nupr1L mRNA levels are also 
induced by this stimulus in the three studied cell lines. Hence, we demonstrated that classical treatments that 
induce p53 activation by different intracellular pathways also increase NUPR1L expression, a finding that is 
consistent with our promoter studies.  
NUPR1L down regulates the transcriptional activity of the NUPR1 promoter  
The close homology between Nupr1 and Nupr1L as well as its ability of being regulated by p53 led us to 
elucidate functional properties of this new p53-target gene, initially as it related to its potential interactions 
with Nupr1. Accordingly, we transfected pancreatic cancer cells with a 6His-Flag-Nupr1L lentiviral vector 
and measured its effects on NUPR1 mRNA expression by RT-qPCR. We find that viral delivery of NUPR1L 
significantly decreased NUPR1 mRNA levels as showed in Figure 7a. To further characterize this effect, we 
used reporter assay using a pGL3-Nupr1-Luc vector containing the previously characterized promoter of 
NUPR1 (-2111 to +229) (Pommier et al., 2012). As shown in Figure 7b, the expression of 6His-Flag-Nupr1L 
results in a 44 ± 9% reduction in NUPR1 promoter activity. Similarly, we observed that NUPR1 promoter 
activity decrease (72 ± 1%) in the presence of p53. Because p53 up-regulates expression of NUPR1L which in 
turn down-regulates expression of NUPR1 and moreover, NUPR1 is down-regulated by p53, we carried on 
luciferase assay in the presence of p53 and silencing NUPR1L by siRNA, in order to know whether the 
regulation exerted by p53 on NUPR1 promoter is or not NUPR1L-dependent. NUPR1L-silenced cells showed 
close values to siControl cells in presence of p53, revealing that the decrease of NUPR1L expression (Figure 
7d) does not interfere on p53-depending regulation of NUPR1 promoter (Figure 7c). These results reveal a 
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coordinated trans-regulation of p53, NUPR1, and NUPR1L into a gene pathway which has an impact on the 
regulation of cell cycle mediated processes.  
Cell cycle arrest induced by NUPR1L is rescued by NUPR1 expression 
FACS-assisted cell cycle analyses carried out in the MiaPaCa-2 pancreatic cancer cell line demonstrate that 
NUPR1L causes an arrest at G1 (58.24 ± 2.95% in cells transduced with GFP- vs. 65.8 ± 3.71% in cells 
transduced with the 6His-Flag-Nupr1L expressing lentivirus, respectively). In addition, Figure 8a shows that 
this effect is accompanied by a decrease in S phase (25.41 ± 2.08% vs. 17.3 ± 1.28% in cells transduced under 
the same conditions). Concomitantly, at the cellular level, we observed that NUPR1L expression induces a 
significant decrease in the viability of MiaPaCa-2 cells (100 ± 1.3% vs. 59.7 ± 0.8% in cells transduced by the 
same set of lentivirus), as shown in Figure 8b. Likewise, if we observe the real-time cell proliferation curves 
we found that NUPR1L-overexpressing cells showed a significant stop in cell proliferation compared with 
GFP-transduced cells from 38 h (Figure 8c). These modifications in the cell cycle, viability and cell 
proliferation are reminiscent of those changes previously observed upon treatment of MiaPaCa-2 cells with 
Nupr1 siRNAs (Grasso et al., 2014; Hamidi et al., 2012b). Thus, taken together, these results led us to 
hypothesize that the effect of NUPR1L on the cell cycle and viability was mediated, at least in part, by down 
regulation of NUPR1. To test this hypothesis we sought to reestablish NUPR1 expression levels in NUPR1L 
overexpressing cells by concomitant lentivirus expression and measured cell cycle progression, cell viability 
and cell proliferation. As shown in Figure 8, NUPR1 expression does not change significantly neither cell 
cycle nor cell viability. Regarding to cell proliferation, NUPR1-overexpressing cells showed a proliferation 
rate higher than GFP-transduced cells. However, the co-expression of NUPR1 with NUPR1L almost 
completely reduces the effects of the latter. In the case of NUPR1 and NUPR1L co-expressing cells, 
proliferation curve was higher than in GFP-transduced cells, reaching values close to NUPR1-overexpressing 
cells. Together, these results suggest that a NUPR1L effect on cell growth is mediated, at least in part, by its 
ability to down-regulate NUPR1.  
Reciprocal regulation of NUPR1L by its homologue NUPR1 
In this work we describe a significant regulation of NUPR1L on the expression of NUPR1 associated to a 
diminution of proliferation in pancreatic cancer cell. The protumoral factor NUPR1 has been subject of study 
for our group during the last decades having demonstrated a crucial role in cancer development and 
progression (Cano et al., 2014; Grasso et al., 2014; Hamidi et al., 2012a; Vasseur et al., 2002). For this 
reason, our next aim was to know if this regulation is reciprocal in order to shed light on the relationship 
between both homologues and the cancer biology. Accordingly, MiaPaca-2 cells were transduced with the 
6His-Flag-Nupr1 lentiviral vector and the NUPR1L expression was evaluated by RT-qPCR using GFP-
transduced cells as control. Cells were cultured in conditioned medium as mock condition and under glucose 
starvation as a metabolic stress condition. No significant difference was found in basal conditions (Figure 9a). 
The induction of a metabolic stress increased sustantialy expression of the NUPR1L (4.5 ± 0.4 folds). 
However, this increment was reduced in the presence of NUPR1 (2.7 ± 0.2 folds). Indeed, NUPR1 silencing 
by siRNA increased slightly the expression of NUPR1L compared to siControl cells under glucose starvation 
conditions (Figure 9b). Effectiveness of specific siRNA was confirmed by RT-qPCR, displaying a reduction 
in the NUPR1 expression of 84% (Figure 9c). Finally, as previously published (Hamidi et al., 2012b), we 
observed that the glucose starvation increased considerably the expression of NUPR1 (352.4 ± 20.7 folds) 
(Figure 9d). Altogether, results revealed that the regulation of NUPR1L by its homologue the NUPR1 tumor 
factor only takes place under stress conditions where the expression of NUPR1 is strongly augmented. 
In summary, we find that in addition to the tumor promoting chromatin protein NUPR1, the human genome 
contains another gene encoding for a highly related isoform. At the molecular level, these two proteins share 
properties between themselves and with members of the HMG family of proteins. Functionally, both proteins 
appear to work downstream of the p53 pathway though playing antagonistic roles on the regulation of cell 
cycle progression, including in the presence of chemotherapeutic drugs. Together, this data expand the 
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knowledge on the repertoire of chromatin proteins, which can mediate p53 signals in pancreatic cancer cells. 
This new knowledge, therefore, has both mechanistic value and biomedical relevance. 
 
Discussion 
In this work we demonstrate that NUPR1L is a new p53-inducible gene that is directed to decrease the 
expression of the NUPR1 tumorigenic gene through the negative regulation of its promoter activity. In 
addition, we also found that overexpression of NUPR1L induces G1 cell cycle arrest and a decrease in cell 
viability and cell proliferation, whereas concomitant overexpression of NUPR1 is able to counter arrest this 
effect indicating that the effect of NUPR1L on cell growth is mediated at least in part by down-regulating 
NUPR1 expression.  
Human NUPR1L gene is located on chromosome 7 (7p11.2) and encodes a 97 aminoacid polypeptide with a 
theoretical molecular mass of 10177.94 Da and a pI of 10.81. Regarding the primary structure, recent in silico 
studies have identified a bipartite nuclear localization signal and a conserved domain which is found in 
several DNA-Binding proteins (Urrutia et al., 2014). In agreement with these predictions, we confirmed its 
nuclear localization using an immunofluorescence analysis of the 6His-Flag-Nupr1L transduced in two cell 
types (Figure2c and 2d). Interestingly, both NUPR1 and NUPR1L proteins are of nuclear localization. Since 
both proteins share subcellular localization and are highly homologous we speculated that they can have a 
functional relationship, both as having common functions or, on the contrary, as acting as a negative 
dominant.  
One of the most interesting observations obtained from this work was the p53-dependency of NUPR1L gene 
expression but most exciting is the fact that we found two functional p53-response elements on the proximal 
region of the NUPR1L promoter, and that both are redundant, suggesting that during the evolution process of 
this gene the p53-dependency was an important criteria of selection. In the same way, we found that cellular 
processes inducing activation of the p53, such as DNA damage induced by anticancer drugs or cell cycle 
arrest induced by serum starvation, activates NUPR1L expression (Figure6), which is in agreement with the 
transactivation experiments (Figure 3). We also found other transcription factors that seem to bind over the 
proximal region of the NUPR1L promoter (Figure3a) however their functionality remains to be defined.  
An apparent contradiction was acted during this study because, on one hand, NUPR1 which is a protumoral 
factor with antiapoptotic activity (Malicet et al., 2006), facilitating the EMT process induced by TGF (Cano 
et al., 2014; Cano et al., 2012; Pommier et al., 2012; Sandi et al., 2011), increasing resistance to anticancer 
treatments (Giroux et al., 2006), facilitating metastasis (Ree et al., 2000) and having a crucial role during 
oncogenic Kras-dependent transformation in pancreatic cancer (Garcia et al., 2014; Hamidi et al., 2012a) by 
bypassing the senescence process (Grasso et al., 2014), but on the other hand, on the contrary, NUPR1L was 
found to be activated by one of the more powerful gene suppressor, p53. In this way, overexpression of 
NUPR1L induces cell cycle arrest and decreases cell viability. Our studies found that in fact the effect we 
observed for NUPR1L was at least in part mediated since NUPR1L clearly down regulates expression of 
NUPR1 and because forced expression of the NUPR1 counter act the effect of NUPR1L overexpression and 
therefore suggesting a very fine regulatory feedback between both structurally-related molecules. 
Interestingly, the high homology, the functional results, as well as the fact of that both factors have been 
proposed to belong to the same protein family (Urrutia et al., 2014), overall, suggests that NUPR1 and 
NUPR1L could be possible paralogous genes arisen by a duplication phenomenon. There are many cases in 
the genome of most organisms, e.g. the hemoglobin genes (Nehrt et al., 2011). In addition, both homologues 
are regulated by p53 but in an opposite manner, suggesting a system of large selective pressure in order to 
maintain an anticancer phenotype through the repression of NUPR1.  
Finally, we aimed to know the effect of the NUPR1 tumor factor on the expression of NUPR1L in order to 
complete this feedback. Results revealed that NUPR1 does not interfere in NUPR1L expression in normal 
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conditions. It was necessary to increase the expression of the tumoral factor through metabolic stress to 
observe a brake in the expression of NUPR1L (Figure 9). Thus, here, we describe a system of two 
homologues with opposite functions where one of them inhibits the expression of the other, which is in turn a 
tumoral factor with a key role in cancer. However, this down-regulation is only reciprocal when the 
expression of NUPR1 is surprisingly high, confirming this anticancer evolutionary pressure above mentioned.  
Nowadays, human cancers represent one of the biggest challenges for modern societies. In fact, it has been 
estimated that by 2020, cancer deaths worldwide could reach 10 million (Szychot et al., 2013). Therefore, one 
of the important aims of science research is the improvement of anti-malignant treatment options to mitigate 
cancer-related morbidity and mortality. Cancer development involves tumor suppression gene inactivation 
and oncogene activation, leading to uncontrolled clonal proliferation. Despite of the efforts to find an 
effective treatment targeting oncogenes or their protein products, the appearance of genetic mechanisms of 
drug resistance has become the principal issue of therapy (Szychot et al., 2013). On the one hand, the tumor 
suppressor p53 is considered one of the major objectives to combat cancer. In fact, several in vivo studies 
have demonstrated an efficient suppression of established tumor after to reinstatement of p53 (Ventura et al., 
2007; Xue et al., 2007). On the other hand, NUPR1, as commented above, is a protumoral factor involved in 
the resistance to the therapy and whose silencing displays an anticancer phenotype. Here, we described a new 
factor that is regulated by the most important tumor suppressor, p53, and represses the expression of a 
protumorogenic factor, NUPR1, displaying an antitumoral phenotype. Thereby, a better understanding of the 
NUPR1L network could be important for the application of p53-based therapies.  
In conclusion, we demonstrated that NUPR1L is a new p53-induced gene which negatively regulates the 
protumoral factor NUPR1. Thus, because of the key role of NUPR1 in cancer, the new information emerging 
from this study has biomedical relevance that aid to a better understanding on the pathobiology of cancer.  
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Similar to Nupr1, Nurp1L displays properties congruent with their role in gene expression regulation: 
(a) Comparison between DNA-binding domains of NUPR1L and NUPR1 with the AT-hook of HMGA1.(b) 
NUPR1L and its closest human homolog NUPR1 share their ability to adopt a helix-loop-helix fold that is 
characteristic of HMGA1. Ribbon representation of their models with helical regions denoted in red and loops 
in white. (c) Homology-based models derived from the PDB complex 1EJY. The models show that a C-
terminal peptide sequence of NUPR1L (KRVAQKLLRGQRKRR) kinds to alpha-importin which mediates 
the nuclear localization of most eukaryotic proteins. The ribbon model shows the C-terminal peptide from 
NUPR1L with blue coloring n basic regions that form the most bonds with the main chain of alpha-importin. 
A space-filling model displays the cavity within alpha-importin which easily accommodates the C-terminal 
peptide of NUPR1L. (d) Two different molecular modeling approaches were used to gain insight into the 
DNA-binding properties of NUPR1L. Both a homology-based approach and a DP-DOCK-based docking 
approach and scoring method reveal that NUPR1L binds to the minor groove of DNA using a DNA binding 
sequence (GRSKGRTRR) that is highly similar to the AT-hook containing transcriptional activator HMGA1. 
HMGA1-based homology models in a ribbon and space-filling representation are shown. (e) DP-DOCK-
based model of full-length NUPRL are shown.  
Figure 2. 
Primary structure analysis and nuclear localization of Nup1L protein: (a) Pairwise alignment of the 
Nupr1 and Nupr1L proteins displaying a 60 % of homology. Residues labeled with a (*) indicate 100% 
identity, residues labeled with (:) indicate positions with conservative substitutions, residues labeled with (.) 
indicate substitutions less conservative. (b) Schematic representation of Nupr1L protein, which contains a 
Nuclear Localization Signal (NLS). The Flag-Nupr1L immunofluorescence in MiaPaca-2 (c) and Hela cells 
(d) reveals its nuclear localization. The cells were transduced with a lentiviral vector (6His-Flag-Nupr1L) and 
were plated on coverslips. The mouse Flag was revelated using Alexa fluorantimouse IgG488. Nuclei are 
stained by blue fluorescent DAPI.  
Figure 3. 
Nupr1L gene is regulated by p53 protein: (a) Diagram of the possible binding sites of different transcription 
factors in the Nupr1L promoter whose sequence is illustrated since the position -643 to +3 considering +1 the 
translation start site. Reporter gene assay for Nupr1L promoter in response to increasing concentration of 
pcDNA3-p53 in Panc-1 (b), MCF-7 (c) and Hela cells (d). The region of the Nupr1L promoter that was 
cloned into pGL3-luciferase vector (pGL3-Nupr1L-Luc) was comprised by the sequence since -245 to +93 
position. Values are expressed as mean ± S.D. of triplicate, from 2 independent experiments. Means sharing 
the same superscript letter are not significantly different from one another (P< 0.05). 
Figure 4. 
Nupr1L promoter contains two p53 regulation functional sites: (a) Schematic representation of the 
different constructions of Nupr1L promoter that were cloned into pGL3-luciferase vector. WT, Nupr1L 
promoter sequence wild type; ΔS1, Nupr1L promoter sequence with the deleted sequence1 by directed 
mutagenesis; ΔS2 Nupr1L promoter sequence with the deleted sequence2 by directed mutagenesis; ΔS1+ΔS2, 
Nupr1L promoter sequence with both deleted sequences (1+2) by directed mutagenesis. The yellow band 
indicates the start codon. (b) Reporter gene assay for the different constructions of Nupr1L promoter (WT, 
ΔS1, ΔS2 and ΔS1+ΔS2) in Panc-1 cells, MCF-7 (c), and Hela cells (d). The bar denominated as control is a 
representation of the different controls corresponding to each construction. Values are expressed as mean ± 
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S.D. of triplicate, from 2 independent experiments. Differences are expressed respect to the control; **P<0.01 
and ***P<0.001; (NS) not significant differences. 
Figure 5.  
p53-dependent expression of Nupr1L. Reporter gene assay for Nupr1L promotor in (a) 3T3 fibroblastes 
(p53
+/+
), (b) 10.1 cell line (p53
-/-
) and (c and d) (10.1)Val5 cell line grown at 39°C and 32°C. Results are 
expressed as fold increase compared with the pGL3 empty vector control. Values are expressed as mean ± 
S.D. of triplicate, from 2 independent experiments. *p<0.05, **P<0.01 and ***P<0.001.   
Figure 6. 
DNA damage treatments and serum starvation induce the Nupr1L gene overexpression: (a) MCF-7 cells 
were treated with increasing concentrations of Oxaliplatin (10, 20 and 40 µM) for 24 h. Capan-2 (b) and Hela 
cells (c) were treated with increasing concentrations of Oxaliplatin (10 and 20 µM) for 18 h. MCF-7 (d), 
Capan-2 (e) and Hela cells (f) were cultured in FBS starvation conditions for 24 h, 60 h and 12 h, 
respectively. mRNA levels of Nupr1L were analyzed by RT-qPCR. The housekeeping gene Cyclophilin was 
used as internal control in order to the normalizing of values. Results are expressed as fold change compared 
with the control ± S.D. Means sharing the same superscript letter are not significantly different from one 
another (P< 0.05). *P<0.05 and **P<0.01. 
Figure 7.  
Nupr1L down-regulates Nupr1 expression. MiaPaca-2 cells were infected by 6His-Flag-Nupr1L lentiviral 
vector. (a) By RT-qPCR, decrease of Nupr1 transcript is observed in cells overexpressing Nupr1L. Western 
Blot shows the increase of NUPR1 protein in transduced cells with the lentiviral 6His-Flag-Nupr1L vector. 
(b) Reporter gene assay for Nupr1. Significant decrease in the activity was observed when cells were co-
transfected with the 6His-Flag-Nupr1L and pGL3-Nupr1-Luc. (c) Similar results were showed at level of 
NUPR1 promoter in presence of p53, displaying a significant decrease in the luciferase activity. Nupr1L 
depletion did not modify the effect of p53 on Nupr1 promoter activity. (d) RT-qPCR of Nupr1L showing the 
effectiveness of specific siRNA. Values are expressed as mean ± S.D. Means sharing the same superscript 
letter are not significantly different from one another. *p<0.05 and ***p<0.001.  
Figure 8. 
Nupr1L decreases the pancreatic cancer cells viability. MiaPaca-2 cells were infected by 6His-Flag-
Nupr1L and 6His-Flag-Nupr1 lentiviral vector, individually and together. GFP overexpressing cells were used 
like control (e) Cytometric cell cycle analysis showing a G1 cell cycle arrest with a significant decrease of S 
phase induced by Nupr1L overexpression and abolished by the concomitant overexpression of Nupr1. (f) Cell 
viability measured by Cell Titer-Blue assay. Decrease of viability is showed in cells infected by 6His-Flag-
Nupr1L vector but not in infected cells byboth lentiviral vectors, 6His-Flag-Nupr1 and 6His-Flag-Nupr1L. 
Cell viability in GFP infected cells was normalized to 100%. Values are expressed as mean ± S.D. Means 
sharing the same superscript letter are not significantly different from one another (P< 0.05). (c) Real-time 
cell proliferation assay using electric impedance as a measure of cell proliferation. Electrical impedance was 
normalized according to the background measurement at time point 0. Impedance measurements were carried 
out for 72 h. Data points represent mean values ± S.D. (n = 3). Results show lower rate of proliferation in 
NUPR1L-overexpressing cells than GFP-transduced cells. The concomitant overexpression of Nupr1 
abolished the effect induced by Nupr1L on the proliferation cell, reaching intermediate values to both infected 
cells (6His-Flag-Nupr1L and 6His-Flag-Nupr1 cells). 
Figure 9.  
Nupr1 decrease the Nupr1L expression under metabolic stress conditions. Expression of Nupr1L or 
Nupr1 by RT-qPCR in MiaPaca-2 cells (a) Nupr1L expression in transduced cells with 6His-Flag-Nupr1 
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lentiviral vector and starved of glucose for 24 h. GFP-overexpressing cells and cultured in conditioned 
medium were used as control. (b) Nupr1L expression in cells treated with siNupr1 or siControl and cultured 
under glucose starvation conditions for 24 h. (c) RT-qPCR of Nupr1 showing the effectiveness of specific 
siRNA.  (d) Increase of Nupr1 expression under glucose starvation conditions. Conditioned medium was used 
as mock treatment. Values are expressed as mean ± S.D. Means sharing the same superscript letter are not 
significantly different from one another. *p<0.05 and ***p<0.001. 
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